RVL Pharmaceuticals plc financial data

Symbol
RVLPQ on OTC
Industry
Pharmaceutical Preparations
Location
400 Crossing Boulevard, Bridgewater, New Jersey
State of incorporation
Ireland
Fiscal year end
December 31
Former names
Osmotica Pharmaceuticals plc (to 1/18/2022), Osmotica Pharmaceuticals Ltd (to 8/22/2018)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % -4.81%
Quick Ratio 2.36 % -11.3%
Debt-to-equity 173 % +70.1%
Return On Equity -155 % -78.1%
Return On Assets -56.8 % -31.6%
Operating Margin -192 % +4.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.5 M shares +0.39%
Common Stock, Shares, Outstanding 99.4 M shares +18.9%
Entity Public Float 44.9 M USD -27%
Common Stock, Value, Issued 994 K USD +18.9%
Weighted Average Number of Shares Outstanding, Basic 99.4 M shares +18.9%
Weighted Average Number of Shares Outstanding, Diluted 99.4 M shares +18.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 36.9 M USD +5.64%
Research and Development Expense 3.1 M USD -34.2%
Operating Income (Loss) -70.8 M USD -1.36%
Nonoperating Income (Expense) 6.95 M USD +39.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -68.5 M USD -4.47%
Net Income (Loss) Attributable to Parent -68.3 M USD -20.8%
Earnings Per Share, Basic -0.72 USD/shares +4%
Earnings Per Share, Diluted -0.72 USD/shares +4%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 1 M USD
Inventory, Net 1.36 M USD +157%
Assets, Current 25.8 M USD -35.9%
Operating Lease, Right-of-Use Asset 365 K USD -58.1%
Intangible Assets, Net (Excluding Goodwill) 13.9 M USD -48.9%
Goodwill 55.8 M USD 0%
Assets 85.4 M USD -31.6%
Accrued Liabilities, Current 7.86 M USD -34.2%
Liabilities, Current 68.4 M USD +269%
Contract with Customer, Liability, Noncurrent 1.2 M USD +500%
Accrued Income Taxes, Noncurrent 71 K USD +5.97%
Deferred Income Tax Liabilities, Net 25 K USD -85.6%
Operating Lease, Liability, Noncurrent 180 K USD -48.4%
Liabilities 69.1 M USD +4.16%
Retained Earnings (Accumulated Deficit) -605 M USD -12.7%
Stockholders' Equity Attributable to Parent 16.3 M USD -72.1%
Liabilities and Equity 85.4 M USD -31.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.82 M USD +56.2%
Net Cash Provided by (Used in) Financing Activities -4.86 M USD -481%
Net Cash Provided by (Used in) Investing Activities -1.23 M USD -12350%
Common Stock, Shares Authorized 400 M shares 0%
Common Stock, Shares, Issued 99.4 M shares +18.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.2 M USD -30.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.54 M USD +211%
Deferred Tax Assets, Valuation Allowance 64.9 M USD +22.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure -85.5%
Operating Lease, Liability 529 K USD -63%
Payments to Acquire Property, Plant, and Equipment 1.3 M USD +4730%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68.3 M USD -25.8%
Lessee, Operating Lease, Liability, to be Paid 538 K USD -63.6%
Operating Lease, Liability, Current 197 K USD -64.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93 K USD -81.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 445 K USD -49.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure -24.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9 K USD -81.3%
Deferred Tax Assets, Operating Loss Carryforwards 26.9 M USD +27.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40 M shares 0%
Unrecognized Tax Benefits 179 K USD +2.29%
Additional Paid in Capital 620 M USD +4.36%
Preferred Stock, Shares Outstanding 0 shares
Current Federal Tax Expense (Benefit) 4.1 M USD
Depreciation, Depletion and Amortization 93 K USD +4.49%
Share-based Payment Arrangement, Expense 2.21 M USD -68.4%
Interest Expense 1.19 M USD -70.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%